[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369111-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369111-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zongertinib-bi-1810631-an-irreversible-her2-tki-spares-egfr-signaling-and-improves-therapeutic-response-research-article","Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response - Research Article","","Mutations in ERBB2 (HER2) drive poor outcomes in 2%–4% of non–small cell lung cancer, while existing ERBB-targeting tyrosine kinase inhibitors fail in HER2-mutant NSCLC because of dose-limiting toxicity or insufficient potency. Zongertinib (BI 1810631), a covalent HER2 inhibitor, potently and selectively blocks HER2 while sparing EGFR. In preclinical models, it suppresses HER2-driven tumor growth and improves responses to antibody–drug conjugates and KRASG12C inhibitors without obvious toxicities, supporting clinical development.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/zongertinib-bi-1810631-an-irreversible-her2-tki-spares-egfr-signaling-and-improves-therapeutic-response-research-article/369111/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zongertinib-bi-1810631-an-irreversible-her2-tki-spares-egfr-signaling-and-improves-therapeutic-response-research-article/369111.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are HER2-targeted inhibitors ineffective in HER2-mutant NSCLC?","Question",{"text":63,"@type":64},"Approved ERBB-targeting tyrosine kinase inhibitors are ineffective due to dose-limiting toxicities or suboptimal potency in HER2-mutant NSCLC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does zongertinib (BI 1810631) act on HER2 and EGFR?",{"text":68,"@type":64},"Zongertinib potently and selectively blocks HER2 while sparing EGFR, inhibiting HER2-dependent driver events.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports zongertinib’s potential beyond preclinical models?",{"text":72,"@type":64},"Preclinical efficacy in HER2-dependent NSCLC xenografts translated into objective responses in patients with HER2-dependent tumors, including cholangiocarcinoma and breast cancer.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369111,1790215607,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","ReseaRch aRticle  \nZongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven  \nCancers   \nBirgit Wilding1, Lydia Woelflingseder1, Anke Baum1, Krzysztof Chylinski1, Gintautas Vainorius1, Neil Gibson2, Irene C. Waizenegger1, Daniel Gerlach1, Martin Augsten1, Fiona Spreitzer1, Yukina Shirai3, Masachika Ikegami3, Sylvia Tilandyová1, Dirk Scharn1, Mark A. Pearson1, Johannes Popow1, Anna C. Obenauf4, Noboru Yamamoto5, Shunsuke Kondo5, Frans L. Opdam6, Annemarie Bruining7, Shinji Kohsaka3, Norbert Kraut1, John V. Heymach8, Flavio Solca1, and Ralph A. Neumüller1  \nMutations in ERBB2 (encoding HER2) occur in 2% to 4% of non–small cell lung  \ncancer (NSCLC) and confer poor prognosis. ERBB-targeting tyrosine kinase inhibitors, approved for treating other HER2-dependent cancers, are ineffective in HER2-mutant NSCLC due to dose-limiting toxicities or suboptimal potency. We report the discovery of zongertinib (BI 1810631), a covalent HER2 inhibitor. Zongertinib potently and selectively blocks HER2, while sparing EGFR, and inhibits the growth of cells dependent on HER2 oncogenic driver events, including HER2-dependent human cancer cells resistant to trastuzumab deruxtecan. Zongertinib displays potent antitumor activity in HER2-dependent human NSCLC xenograft models and enhances the activities of antibody–drug conjugates and KRASG12C inhibitors without causing obvious toxicities. The preclinical efficacy of zongertinib translates in objective responses in patients with HER2-dependent tumors, including cholangiocarcinoma (SDC4–NRG1 fusion) and breast cancer (V777L HER2 mutation), thus supporting the ongoing clinical development of zongertinib.  \nSIGnIFICAnCE: HER2-mutant NSCLC poses a challenge in the clinic due to limited options for targeted therapies. Pan-ERBB blockers are limited by wild-type EGFR–mediated toxicity. Zongertinibis a highly potent and wild-type EGFR–sparing HER2 inhibitor that is active in HER2-driven tumorsin the preclinical and clinical settings.  \nintRoduction  \nThe ERBB family receptor tyrosine kinases (RTK) are important for normal development and physiology (1–3) . In humans, the ERBB family includes the following members: EGFR, also referred to as HER1 (encoded by EGFR), HER2 (encoded by ERBB2), HER3 (encoded by ERBB3), and HER4 (encoded by ERBB4) . These receptors form homodimers and heterodimers upon ligand activation. HER2 lacks a known ligand but is the preferred dimerization partner of other family members. The MAPK and PI3K/AKT pathways constitute the two major signaling pathways downstream of ERBB family receptors (2) .  \n1Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria. 2Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 3Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan. 4Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.  \n5Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. 6Division of Medical Oncology, Department of Clinical Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, the Netherlands. 7Department of Radiology, Antonivan Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, the Netherlands. 8Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Corresponding Authors: Birgit Wilding, Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, Vienna 1121, Austria. E-mail: [birgit.wilding@boehringer-ingelheim. com](birgit.wilding@boehringer-ingelheim. com); and Ralph A. Neumüller, Boehringer Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11,  \nVienna 1121, Austria. E-mail: [ralph.neumueller@boehringer-ingelheim.com](ralph.neumueller@boehringer-ingelheim.com)  \nCancer Discov 2025;15:119–38  \ndoi: 10. 1158/2159-8290","cbCaisnkHJSS5qmu","https://ap.wps.com/l/cbCaisnkHJSS5qmu","pdf",7772701,"English","# Introduction\n## ERBB family signaling and HER2 biology\n# Zongertinib and therapeutic rationale\n## Covalent HER2 inhibition and EGFR sparing","[{\"question\":\"Why are HER2-targeted inhibitors ineffective in HER2-mutant NSCLC?\",\"answer\":\"Approved ERBB-targeting tyrosine kinase inhibitors are ineffective due to dose-limiting toxicities or suboptimal potency in HER2-mutant NSCLC.\"},{\"question\":\"How does zongertinib (BI 1810631) act on HER2 and EGFR?\",\"answer\":\"Zongertinib potently and selectively blocks HER2 while sparing EGFR, inhibiting HER2-dependent driver events.\"},{\"question\":\"What evidence supports zongertinib’s potential beyond preclinical models?\",\"answer\":\"Preclinical efficacy in HER2-dependent NSCLC xenografts translated into objective responses in patients with HER2-dependent tumors, including cholangiocarcinoma and breast cancer.\"}]","Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response - Research Article | PDF",1790180822,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bc9b4e8d0fea9d397df42d60bd72c9e.webp",983,1315,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87dcc1a5b4e18c785cc006dd1f2a208a.webp",982,1314,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a1aa119e091f4bc697aed4930a3efd1.webp",981,1312,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cf2a5b7a33688dfa2a968a25c27033b.webp",980,1311]